Literature DB >> 20600451

Identification of an alternate splice form of tapasin in human melanoma.

Alan Belicha-Villanueva1, Michelle Golding, Sarah McEvoy, Nilofar Sarvaiya, Peter Cresswell, Sandra O Gollnick, Naveen Bangia.   

Abstract

Assembly of major histocompatibility complex (MHC) class I molecules with peptide in the endoplasmic reticulum requires the assistance of tapasin. Alternative splicing, which is known to regulate many genes, has been reported for tapasin only in the context of mutations. Here, we report on an alternate splice form of tapasin (tpsnΔEx3) derived from a human melanoma cell line that does not appear to be caused by mutations. Excision of exon 3 results in deletion of amino acids 70 to 156 within the beta barrel region, but the membrane proximal Ig domain, the transmembrane domain, and cytoplasmic tail of tapasin are intact. Introduction of tpsnΔEx3 into a tapasin-deficient cell line does not restore MHC class I expression at the cell surface. Similar to a previously described tapasin mutant (tpsnΔN50), tpsnΔEx3 interacts with TAP. Therefore, we used these altered forms of tapasin to test the importance of MHC class I interaction with TAP. In the presence of wild-type tapasin, transfection of tpsnΔN50, but not tpsnΔEx3, reduced MHC class I expression at the cell surface likely due its ability to compete MHC class I molecules from TAP. Together these findings suggest that tumor cells may contain alternate splice forms of tapasin which may regulate MHC class I antigen presentation. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20600451      PMCID: PMC2952442          DOI: 10.1016/j.humimm.2010.05.019

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  50 in total

1.  Generation of a functional, soluble tapasin protein from an alternatively spliced mRNA.

Authors:  B Gao; A Williams; A Sewell; T Elliott
Journal:  Genes Immun       Date:  2004-03       Impact factor: 2.676

2.  Endoplasmic reticulum chaperone-specific monoclonal antibodies for flow cytometry and immunohistochemical staining.

Authors:  T Ogino; X Wang; S Kato; N Miyokawa; Y Harabuchi; S Ferrone
Journal:  Tissue Antigens       Date:  2003-11

3.  Disulfide bond isomerization and the assembly of MHC class I-peptide complexes.

Authors:  Tobias P Dick; Naveen Bangia; David R Peaper; Peter Cresswell
Journal:  Immunity       Date:  2002-01       Impact factor: 31.745

4.  The ER aminopeptidase ERAP1 enhances or limits antigen presentation by trimming epitopes to 8-9 residues.

Authors:  Ian A York; Shih-Chung Chang; Tomo Saric; Jennifer A Keys; Janice M Favreau; Alfred L Goldberg; Kenneth L Rock
Journal:  Nat Immunol       Date:  2002-11-18       Impact factor: 25.606

5.  An essential role for tripeptidyl peptidase in the generation of an MHC class I epitope.

Authors:  Ulrike Seifert; Concepción Marañón; Ayelet Shmueli; Jean-François Desoutter; Lisa Wesoloski; Katharina Janek; Peter Henklein; Susanne Diescher; Muriel Andrieu; Henri de la Salle; Toni Weinschenk; Hansjörg Schild; Diego Laderach; Anne Galy; Gaby Haas; Peter-M Kloetzel; Yuval Reiss; Anne Hosmalin
Journal:  Nat Immunol       Date:  2003-02-24       Impact factor: 25.606

6.  Association of tapasin and HLA class I antigen down-regulation in primary maxillary sinus squamous cell carcinoma lesions with reduced survival of patients.

Authors:  Takeshi Ogino; Nobuyuki Bandoh; Tatsuya Hayashi; Naoyuki Miyokawa; Yasuaki Harabuchi; Soldano Ferrone
Journal:  Clin Cancer Res       Date:  2003-09-15       Impact factor: 12.531

7.  Regulation of the expression of mouse TAP-associated glycoprotein (tapasin) by cytokines.

Authors:  Karin Abarca-Heidemann; Sonja Friederichs; Thorsten Klamp; Ulrich Boehm; Lisbeth A Guethlein; Bodo Ortmann
Journal:  Immunol Lett       Date:  2002-10-01       Impact factor: 3.685

8.  Tapasin enhances MHC class I peptide presentation according to peptide half-life.

Authors:  Mark Howarth; Anthony Williams; Anne B Tolstrup; Tim Elliott
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-30       Impact factor: 11.205

9.  Tapasin is a facilitator, not an editor, of class I MHC peptide binding.

Authors:  Angela L Zarling; Chance John Luckey; Jarrod A Marto; Forest M White; Cynthia J Brame; Anne M Evans; Paul J Lehner; Peter Cresswell; Jeffrey Shabanowitz; Donald F Hunt; Victor H Engelhard
Journal:  J Immunol       Date:  2003-11-15       Impact factor: 5.422

10.  Bap29/31 influences the intracellular traffic of MHC class I molecules.

Authors:  Marie-Eve Paquet; Myrna Cohen-Doyle; Gordon C Shore; David B Williams
Journal:  J Immunol       Date:  2004-06-15       Impact factor: 5.422

View more
  7 in total

1.  Productive association between MHC class I and tapasin requires the tapasin transmembrane/cytosolic region and the tapasin C-terminal Ig-like domain.

Authors:  Laura C Simone; Corey J Georgesen; Peter D Simone; Xiaojian Wang; Joyce C Solheim
Journal:  Mol Immunol       Date:  2011-12-12       Impact factor: 4.407

2.  Loss of tapasin in human lung and colon cancer cells and escape from tumor-associated antigen-specific CTL recognition.

Authors:  Yosuke Shionoya; Takayuki Kanaseki; Sho Miyamoto; Serina Tokita; Ayumi Hongo; Yasuhiro Kikuchi; Vitaly Kochin; Kazue Watanabe; Ryota Horibe; Hiroshi Saijo; Tomohide Tsukahara; Yoshihiko Hirohashi; Hiroki Takahashi; Noriyuki Sato; Toshihiko Torigoe
Journal:  Oncoimmunology       Date:  2017-01-03       Impact factor: 8.110

Review 3.  Disulfide reduction in the endocytic pathway: immunological functions of gamma-interferon-inducible lysosomal thiol reductase.

Authors:  Karen Taraszka Hastings; Peter Cresswell
Journal:  Antioxid Redox Signal       Date:  2011-04-20       Impact factor: 8.401

Review 4.  GILT: Shaping the MHC Class II-Restricted Peptidome and CD4(+) T Cell-Mediated Immunity.

Authors:  Karen Taraszka Hastings
Journal:  Front Immunol       Date:  2013-12-04       Impact factor: 7.561

5.  TAPBPR isoforms exhibit altered association with MHC class I.

Authors:  Keith M Porter; Clemens Hermann; James A Traherne; Louise H Boyle
Journal:  Immunology       Date:  2014-06       Impact factor: 7.397

Review 6.  Cancer Neoantigens: Challenges and Future Directions for Prediction, Prioritization, and Validation.

Authors:  Elizabeth S Borden; Kenneth H Buetow; Melissa A Wilson; Karen Taraszka Hastings
Journal:  Front Oncol       Date:  2022-03-03       Impact factor: 6.244

Review 7.  Targeting Neoepitopes to Treat Solid Malignancies: Immunosurgery.

Authors:  Eric de Sousa; Joana R Lérias; Antonio Beltran; Georgia Paraschoudi; Carolina Condeço; Jéssica Kamiki; Patrícia Alexandra António; Nuno Figueiredo; Carlos Carvalho; Mireia Castillo-Martin; Zhe Wang; Dário Ligeiro; Martin Rao; Markus Maeurer
Journal:  Front Immunol       Date:  2021-07-15       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.